An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria

Journal of the American Society of Nephrology

Volumn 28, Issue 2, 2017, Pages 494-503

  Liebow, Abigail ^a   Li, Xingsheng ^b   Racie, Timothy ^a   Hettinger, Julia ^a   Bettencourt, Brian R ^a   Najafian, Nader ^a   Haslett, Patrick ^a   Fitzgerald, Kevin ^a   Holmes, Ross P ^b   Erbe, David ^a   Querbes, William ^a   Knight, John ^b  

^a ALNYLAM PHARMACEUTICALS   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE GLYOXYLATE AMINOTRANSFERASE; ALANINE GLYOXYLATE AMINOTRANSFERASE 1; DRINKING WATER; ETHYLENE GLYCOL; GLYCOLIC ACID; HYDROXY ACID OXIDASE A; MESSENGER RNA; OXALIC ACID; UNCLASSIFIED DRUG; ALCOHOL DEHYDROGENASE; OXALIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG TARGETING; GENE SILENCING; GENETIC MODEL; LIVER CELL; MACACA FASCICULARIS; MALE; MOUSE; MULTIPLE DRUG DOSE; NONHUMAN; NONVIRAL GENE THERAPY; OXALOSIS 1; PRIORITY JOURNAL; RAT; RNAI THERAPEUTICS; SINGLE DRUG DOSE; ANIMAL; DISEASE MODEL; ENZYMOLOGY; GENETICS; HYPEROXALURIA, PRIMARY; LIVER; METABOLISM; PRIMATE;

ALCOHOL OXIDOREDUCTASES; ANIMALS; DISEASE MODELS, ANIMAL; GENE SILENCING; HYPEROXALURIA, PRIMARY; LIVER; MALE; MICE; OXALATES; PRIMATES; RATS; RNA, MESSENGER; RNAI THERAPEUTICS;

EID: 85016299478     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2016030338     Document Type: Article

References (32)

1. Hoppe B: An update on primary hyperoxaluria. Nat Rev Nephrol 8: 467-475, 2012
2. Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC; Rare Kidney Stone Consortium: Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria. J AmSoc Nephrol 26: 2559-2570, 2015
3. Kamoun A, Lakhoua R: End-stage renal disease of the Tunisian child: Epidemiology, etiologies, and outcome. Pediatr Nephrol 10: 479-482, 1996
4. Al-Eisa AA, Samhan M, Naseef M: End-stage renal disease in Kuwaiti children: An 8-year experience. Transplant Proc 36: 1788-1791, 2004
5. Boualla L, TajirM, Oulahiane N, Lyahyai J, Laarabi FZ, Chafai Elalaoui S, Soulami K, Ait Ouamar H, Sefiani A: AGXT Gene Mutations and Prevalence of Primary Hyperoxaluria Type 1 inMoroccan Population. Genet Test Mol Biomarkers 19: 623-628, 2015
6. Rare Kidney Stone Consortium: Primary Hyperoxaluria; 25-September-2015. Available at: Http://www.rarekidneystones.org/hyperoxaluria. Accessed December 17, 2015
7. Cochat P, Rumsby G: Primary hyperoxaluria. N Engl J Med 369: 649-658, 2013
8. Zhao F, Bergstralh EJ, Mehta RA, Vaughan LE, Olson JB, Seide BM, Meek AM, Cogal AG, Lieske JC, Milliner DS; Investigators of Rare Kidney Stone Consortium: Predictors of Incident ESRD among Patients with PrimaryHyperoxaluria Presenting Prior to Kidney Failure. Clin JAm Soc Nephrol 11: 119-126, 2016
9. Mandrile G, van Woerden CS, Berchialla P, Beck BB, Acquaviva Bourdain C, Hulton SA, Rumsby G; OxalEurope Consortium: Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int 86: 1197-1204, 2014
10. Frishberg Y, Zeharia A, Lyakhovetsky R, Bargal R, Belostotsky R: Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria. J Med Genet 51: 526-529, 2014
11. MurrayMS, Holmes RP, LowtherWT: Active site and loop 4movements within human glycolate oxidase: Implications for substrate specificity and drug design. Biochemistry 47: 2439-2449, 2008
12. Chen ZW, Vignaud C, Jaafar A, Lévy B, Guéritte F, Guénard D, Lederer F, Mathews FS: High resolution crystal structure of rat long chain hydroxy acid oxidase in complex with the inhibitor 4-carboxy-5-[(4-chlorophenyl)sulfanyl]-1, 2, 3-thiadiazole. Implications for inhibitor specificity and drug design. Biochimie 94: 1172-1179, 2012
13. Martin-Higueras C, Luis-Lima S, Salido E: Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in aMouseModel of Primary Hyperoxaluria Type I. Mol Ther 24: 719-725, 2016
14. Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R, de Fougerolles T, Maraganore J: A status report on RNAi therapeutics. Silence 1, 2010
15. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001
16. Elbashir SM, Lendeckel W, Tuschl T: RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15: 188-200, 2001
17. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Röhl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, ZedalisW, Koteliansky V, ManoharanM, Vornlocher HP, MacLachlan I: RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114, 2006
18. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, Hutabarat RM, Clausen VA, Karsten V, Cehelsky J, Nochur SV, Kotelianski V, Horton J, Mant T, Chiesa J, Ritter J, Munisamy M, Vaishnaw AK, Gollob JA, Simon A: Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serumLDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383: 60-68, 2014
19. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, Chiesa J, Warrington S, Tranter E, Munisamy M, Falzone R, Harrop J, Cehelsky J, Bettencourt BR, GeisslerM, Butler JS, Sehgal A, Meyers RE, Chen Q, Borland T, Hutabarat RM, Clausen VA, Alvarez R, Fitzgerald K, Gamba-Vitalo C, Nochur SV, Vaishnaw AK, Sah DW, Gollob JA, Suhr OB: Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 369: 819-829, 2013
20. Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q, Hoekstra M, Kandasamy P, Kel'in AV, Milstein S, Taneja N, O'Shea J, Shaikh S, Zhang L, van der Sluis RJ, Jung ME, Akinc A, Hutabarat R, Kuchimanchi S, Fitzgerald K, Zimmermann T, van Berkel TJ, Maier MA, Rajeev KG, Manoharan M: Multivalent N-acetylgalactosamineconjugated siRNA localizes in hepatocytes and elicits robust RNAimediated gene silencing. J Am Chem Soc 136: 16958-16961, 2014
21. Geffen I, Spiess M: Asialoglycoprotein receptor. Int Rev Cytol 137B: 181-219, 1992
22. Wu J, Nantz MH, Zern MA: Targeting hepatocytes for drug and gene delivery: Emerging novel approaches and applications. Front Biosci 7: D717-d725, 2002
23. Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T, Hettinger J, Carioto M, Jiang Y, Brodsky J, Prabhala H, Zhang X, Attarwala H, Hutabarat R, FosterD, Milstein S, Charisse K, Kuchimanchi S, MaierMA, Nechev L, Kandasamy P, Kel'in AV, Nair JK, Rajeev KG, Manoharan M, Meyers R, Sorensen B, Simon AR, Dargaud Y, Negrier C, Camire RM, Akinc A: An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 21: 492-497, 2015
24. YasudaM, Gan L, Chen B, Kadirvel S, Yu C, Phillips JD, NewMI, Liebow A, Fitzgerald K, Querbes W, Desnick RJ: RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice. Proc Natl Acad Sci U S A 111: 7777-7782, 2014
25. Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, Jayaraman M, Rajeev KG, Cantley WL, Dorkin JR, Butler JS, Qin L, Racie T, Sprague A, Fava E, Zeigerer A, Hope MJ, Zerial M, Sah DW, Fitzgerald K, Tracy MA, Manoharan M, Koteliansky V, Fougerolles A, Maier MA: Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18: 1357-1364, 2010
26. Jayaraman M, Ansell SM, Mui BL, Tam YK, Chen J, Du X, Butler D, Eltepu L, Matsuda S, Narayanannair JK, Rajeev KG, Hafez IM, Akinc A, Maier MA, Tracy MA, Cullis PR, Madden TD, Manoharan M, Hope MJ: Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl 51: 8529-8533, 2012
27. Baker PR, Cramer SD, Kennedy M, Assimos DG, Holmes RP: Glycolate and glyoxylate metabolism in HepG2 cells. Am J Physiol Cell Physiol 287: C1359-C1365, 2004
28. Knight J, Holmes RP, Cramer SD, Takayama T, Salido E:Hydroxyproline metabolism in mouse models of primary hyperoxaluria. Am J Physiol Renal Physiol 302: F688-F693, 2012
29. Li X, Knight J, Todd Lowther W, Holmes RP: Hydroxyproline metabolism in a mouse model of Primary Hyperoxaluria Type 1. Biochim Biophys Acta 1852: 2700-2705, 2015
30. Salido EC, Li XM, Lu Y, Wang X, Santana A, Roy-ChowdhuryN, TorresA, Shapiro LJ, Roy-Chowdhury J: Alanine-glyoxylate aminotransferasedeficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer. Proc Natl Acad Sci U S A 103: 18249-18254, 2006
31. Li X, Knight J, Fargue S, Buchalski B, Guan Z, Inscho EW, Liebow A, Fitzgerald K, QuerbesW, Todd Lowther W, Holmes RP: Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase. BiochimBiophys Acta 1862: 233-239, 2016
32. Dutta C, Avitahl-Curtis N, Pursell N, Larsson Cohen M, Holmes B, Diwanji R, Zhou W, Apponi L, Koser M, Ying B, Chen D, Shui X, Saxena U, Cyr WA, Shah A, Nazef N, Wang W, Abrams M, Dudek H, Salido E, Brown BD, Lai C: Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1. Mol Ther 24: 770-778, 2016